Limno Pharma, S.L.

Limno Pharma is a pharmaceutical company dedicated to the research and development of new drugs for the treatment of ophthalmic diseases based on two exclusively licensed patents. Our initial focus is on the treatment of two retinal degenerative diseases, retinitis pigmentosa (RP) and age-related macular degeneration (AMD). More than 200M people suffer retinal degenerative pathologies, and only 10% have an effective treatment. All marketed drugs have to be administered as intraocular injections. Administration as intraocular injection is very invasive, agressive for the eye, resulting in low treatment compliance. 

Our firts product, LIM21 is a chemical derivative of a natural product which shows high efficacy decreasing the symptoms of RP and dry AMD in mouse models. The main competitive advantage of LIM21 over marketed drugs and others under development, is the administration as eye drops.  Due to its mechanism of action, LIM21 could be benefitial to all patients suffering RP and dry-AMD, and, since it is a small molecule, it is easy to manufacture, inexpensive and potentially less inmunogenic that biomolecules. 

Our pipeline also includes other products, LIM24 and LIM109, that are being developed for other retinal degenerative pathologies (wet AMD and diabetic retinopathy).